Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorders, And Immunological Disorders)"
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals (SHPH) has been granted a European patent (EP3737376) for 'Selective Histone Deacetylase Inhibitors for the Treatment of Human Diseases', covering a range of conditions including cancers, neurological, and immunological disorders. This patent strengthens SHPH's intellectual property portfolio and potentially enhances its position in developing treatments for these diseases.
March 18, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals' new European patent for 'Selective Histone Deacetylase Inhibitors' could significantly enhance its R&D capabilities and market position in treating various serious diseases.
The granting of a European patent to Shuttle Pharmaceuticals for a broad range of treatments signifies a major advancement in its research and development efforts. This patent not only strengthens its intellectual property portfolio but also potentially opens up new avenues for the development and commercialization of treatments for cancers, neurological, and immunological disorders. Given the broad applicability of the patent, it is likely to have a positive impact on SHPH's stock in the short term as it enhances the company's value proposition to investors and partners.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90